ClinicalTrials.gg
CompletedNCT05890001Updated Sep 26, 2025

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

A Phase 3 interventional study of BLI5100 in Non-erosive Reflux Disease and Erosive Esophagitis, sponsored by Braintree Laboratories. Completed at 60 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by Braintree Laboratories (part of Sebela Pharmaceuticals) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).

02

Conditions studied

  • Non-erosive Reflux Disease
  • Erosive Esophagitis
03

In context

Non-Erosive Reflux Disease

47 studies on the registry are indexed under Non-Erosive Reflux Disease; 8 are open to participants now.

This study's enrollment of 400 is above the median of 160 across 34 interventional studies indexed under Non-Erosive Reflux Disease.

Browse Non-Erosive Reflux Disease studies →

Lead sponsor

Braintree Laboratories is the lead sponsor of 49 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

First submitted after Braintree Laboratories became part of Sebela Pharmaceuticals.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have completed the BLI5100-301 or BLI5100-302 study with no serious AE (SAE) related to study drug and no major Protocol Deviations;
  2. Able to understand and comply with the protocol requirements;
  3. Willing and able to provide written at Screening;
  4. Is a female of non-, or If a female of childbearing potential, agrees to use an acceptable form of and avoid egg donation from the Screening Visit until 6 months after the last dose of study drug;
  5. If a male, agrees to use an acceptable form of birth control from the Screening Visit until 3 months after the last dose of study drug;
  6. If a male, agrees to abstain from sperm donation through 3 months after administration of the last dose of study drug;
  7. Have documented healed EE (BLI5100-301 study patients only).

Exclusion criteria

Exclusion Criteria:

  1. History of alcoholism, or substance abuse/addiction in the year before enrollment in the BLI5100-301 and BLI5100-302 studies;

    • Note: Patients on prescribed opioids are eligible to participate if they have been on a stable dose for the duration of the BLI5100-301 and BLI5100-302 studies.
    • Note: Retesting of a positive urine drug screen requires Medical Monitor approval. Positive urine drug screen for all drugs will require verification of prescription for the positive tested substance.
  2. A diagnosis of manic-depression, anxiety disorder, panic disorder, somatoform disorder, personality disorder, or other psychological disorder is exclusionary, unless the patient is asymptomatic and well-controlled. Stable treatment, including non-medical therapy, is preferred, but minor adjustments can be made and should be consulted with the Medical Monitor;
  3. Current use of antipsychotics, antidepressants, anxiolytics, or prescription sleeping medications, with the exception of a stable dose for the duration of the BLI5100-301 and BLI5100-302 studies;
  4. Requirement of persistent (>3 times per week for >30 days) use of non-steroidal anti-inflammatory drugs (NSAIDs) during the course of the study;

    o Note: Low-dose (≤100 mg/day) aspirin is allowed provided that it has been used for prophylaxis prior to study participation.

  5. If a female, is pregnant, breastfeeding, or planning to become pregnant during the study or within 6 months after the last dose of study drug;
  6. Abnormal laboratory results with clinical relevance at Screening as follows:

    • (AST), alanine aminotransferase (ALT), or alkaline phosphatase level of ≥2 × (ULN);
    • Total level of ≥2 × ULN, unless Gilbert's syndrome is confirmed when direct bilirubin is ≤0.3 mg/dL;
    • Estimated \<30 mL/min.
    • Note: A lab value obtained during the Screening period may be retested once with Medical Monitor approval.
  7. Abnormal of clinical significance;
  8. Involvement in another clinical study (other than BLI5100-301 and BLI5100-302 studies) within 4 weeks of initiation of study drug;
  9. Any other condition that would confound study endpoints or adversely affect patient compliance with the study procedures in the medical judgment of the Investigator or Medical Monitor based on previous medical history or findings on Screening assessments.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    BLI5100 Low Dose

    Patients will take BLI5100 Low Dose once daily, orally, for up to 29 weeks.

    Drug: BLI5100

  • Experimental
    BLI5100 High Dose

    Patients will take BLI5100 High Dose once daily, orally, for up to 29 weeks.

    Drug: BLI5100

Interventions

  • Patients will take BLI5100 once daily, orally, for up to 29 weeks.

06

What researchers measure

Primary outcomes

  1. Frequency of treatment-emergent adverse events

    Time frame: 31 Weeks

07

Study locations

60 sites
  • Research Site 24
    Huntsville, Alabama 35801, United States
  • Research Site 62
    Phoenix, Arizona 85018, United States
  • Research Site 27
    Tucson, Arizona 85712, United States
  • Research Site 87
    Little Rock, Arkansas 72211, United States
  • Research Site 117
    North Little Rock, Arkansas 72117, United States
  • Research Site 94
    Chula Vista, California 91910, United States
  • Research Site 10
    Huntington Park, California 90255, United States
  • Research Site 55
    La Mesa, California 91942, United States
  • Research Site 72
    Los Angeles, California 90017, United States
  • Research Site 54
    Los Angeles, California 90057, United States
  • Research Site 13
    Santa Ana, California 92704, United States
  • Research Site 41
    Santa Maria, California 93458, United States
  • Research Site 108
    Cooper City, Florida 33024, United States
  • Research Site 91
    Doral, Florida 33172, United States
  • Research Site 78
    Homestead, Florida 33030, United States
  • Research Site 23
    Maitland, Florida 32751, United States
  • Research Site 38
    Miami, Florida 33134, United States
  • Research Site 43
    Miami, Florida 33136, United States
  • Research Site 67
    Miami, Florida 33155, United States
  • Research Site 92
    Miami, Florida 33173, United States
  • Research Site 71
    Miami, Florida 33186, United States
  • Research Site 42
    Miami Lakes, Florida 33014, United States
  • Research Site 17
    New Port Richey, Florida 34653, United States
  • Research Site 90
    Ocoee, Florida 34761, United States
  • Research Site 05
    Palmetto Bay, Florida 33157, United States
  • Research Site 11
    Sunrise, Florida 33351, United States
  • Research Site 46
    Viera, Florida 32940, United States
  • Research Site 59
    Sandy Springs, Georgia 30328, United States
  • Research Site 01
    Gurnee, Illinois 60031, United States
  • Research Site 02
    Oak Lawn, Illinois 60453, United States
  • Research Site 45
    Houma, Louisiana 70363, United States
  • Research Site 12
    Marrero, Louisiana 70072, United States
  • Research Site 48
    Metairie, Louisiana 70006, United States
  • Research Site 34
    New Orleans, Louisiana 70127, United States
  • Research Site 111
    Chesterfield, Missouri 63005, United States
  • Research Site 06
    Las Vegas, Nevada 89106, United States
  • Research Site 64
    Reno, Nevada 89511, United States
  • Research Site 35
    Brooklyn, New York 11235, United States
  • Research Site 07
    Great Neck, New York 11023, United States
  • Research Site 28
    Hartsdale, New York 10530, United States
  • Research Site 49
    New York, New York 10033, United States
  • Research Site 40
    Rochester, New York 14609, United States
  • Research Site 75
    Fayetteville, North Carolina 28304, United States
  • Research Site 20
    Columbus, Ohio 43213, United States
  • Research Site 88
    Columbus, Ohio 43215, United States
  • Research Site 109
    Mentor, Ohio 44060, United States
  • Research Site 110
    Westlake, Ohio 44145, United States
  • Research Site 60
    Nashville, Tennessee 37203, United States
  • Research Site 103
    Nashville, Tennessee 37211, United States
  • Research Site 100
    Bellaire, Texas 77401, United States
  • Research Site 98
    Dallas, Texas 75230, United States
  • Research Site 99
    Forney, Texas 75126, United States
  • Research Site 29
    Lewisville, Texas 75057, United States
  • Research Site 32
    Pearland, Texas 77584, United States
  • Research Site 30
    Red Oak, Texas 75154, United States
  • Research Site 22
    San Antonio, Texas 78209, United States
  • Research Site 26
    San Antonio, Texas 78229, United States
  • Research Site 21
    San Antonio, Texas 78249, United States
  • Research Site 65
    Sandy City, Utah 84092, United States
  • Research Site 16
    South Ogden, Utah 84405, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Oct 2024, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2023
First posted
Jun 5, 2023
StartActual
Apr 5, 2023
Primary completionActual
Oct 8, 2024
CompletionActual
Oct 8, 2024
Results delay requested
Sep 19, 2025
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05890001
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Apr 5, 2023
Primary completion
Oct 8, 2024
Completion
Oct 8, 2024
Last update
Sep 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion